---
title: "Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294061137.md"
description: "Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company (Nasdaq: PVLA), will release its second quarter 2026 financial report on August 4, 2026, before the market opens. The company, based in Wayne, Pa., focuses on developing therapies for rare skin diseases and vascular malformations lacking FDA-approved treatments. Palvella will host an investor conference call at 8:30 a.m. ET on the same day to review the results and offer a corporate update."
datetime: "2026-07-28T11:33:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294061137.md)
  - [en](https://longbridge.com/en/news/294061137.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294061137.md)
generator: "portal-rs"
---

# Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company (Nasdaq: PVLA), will release its second quarter 2026 financial report on August 4, 2026, before the market opens. The company, based in Wayne, Pa., focuses on developing therapies for rare skin diseases and vascular malformations lacking FDA-approved treatments. Palvella will host an investor conference call at 8:30 a.m. ET on the same day to review the results and offer a corporate update.

### Related Stocks

- [PVLA.US](https://longbridge.com/en/quote/PVLA.US.md)

## Related News & Research

- [PVLA: Advanced NDA submission and clinical pipeline with $250.6M cash; net loss widened to $21.9M](https://longbridge.com/en/news/294821621.md)
- [Palvella Therapeutics posts corporate presentation highlighting Phase 3 SELVA wins, NDA rolling review and $262M cash](https://longbridge.com/en/news/292675219.md)
- [Coya Therapeutics posts September 2026 investor presentation on neurodegeneration pipeline](https://longbridge.com/en/news/297669200.md)
- [Vytrus Biotech says European skin rejuvenation patent validated in seven countries](https://longbridge.com/en/news/298226256.md)
- [Regeneron announces Q3 2026 dividend of R$ 0.05 per unit](https://longbridge.com/en/news/297814808.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**